drugset / Trial / NCT00840034
A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary purpose is to study the efficacy, safety, and tolerability of LY2216684 as an adjunctive treatment for participants with major depressive disorder (MDD), who were identified as partial responders to an adequate course of treatment with a selective serotonin reuptake inhibitor (SSRI) (as defined by history).
Timeline
- Start
- 2009-02
- Primary completion
- 2010-01
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | edivoxetine | Small molecule | 9 mg | Oral |
| Subject | edivoxetine | Small molecule | 12 mg | Oral |
| Subject | edivoxetine | Small molecule | 18 mg | Oral |